A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
USANA Health Sciences, Inc. is a global direct selling and direct-to-consumer nutrition, personal health and wellness company. In 2024, we generated $855 million in net sales and finished the year with approximately 454,000 direct selling active Customers. We were founded in 1992 by Myron W. Wentz, Ph.D. and since that time, we have developed and manufactured high quality, science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness. We are committed to continuous product innovation and sound scientific research. We have operations in 25 geographic markets worldwide. Historically, we have distributed our products through the direct selling channel, because we believe it is conducive to our vision of improving the overall health and nutrition of individuals and families around the world. In December 2024, we acquired a 78.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 913M | 855M | 921M | 1.2B | 1.1B | 1.1B |
| Net Income | 17M | 42M | 64M | 117M | 125M | 101M |
| EPS | $0.90 | $2.19 | $3.30 | $5.73 | $5.86 | $4.41 |
| Free Cash Flow | 19M | 51M | 56M | 108M | 145M | 110M |
| ROIC | 3.9% | 14.1% | 34.7% | 79.6% | 95.3% | 83.5% |
| Gross Margin | 79.2% | 81.1% | 80.8% | 81.6% | 81.6% | 82.3% |
| Debt/Equity | 0.00 | 0.30 | 0.27 | 0.37 | 0.45 | 0.47 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 42M | 66M | 93M | 170M | 176M | 146M |
| Operating Margin | 4.6% | 7.8% | 10.1% | 14.3% | 15.6% | 13.8% |
| ROE | 3.2% | 8.2% | 12.8% | 26.8% | 28.2% | 28.6% |
| Shares Outstanding | 18M | 19M | 19M | 20M | 21M | 23M |
| Metric | 2017 | 2018 | 2019 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.0B | 1.2B | 1.1B | 1.1B | 1.2B | 921M | 855M | 913M |
| Gross Margin | 82.9% | 83.1% | 82.3% | 81.6% | 81.6% | 80.8% | 81.1% | 79.2% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 133M | 188M | 146M | 176M | 170M | 93M | 66M | 42M |
| Op. Margin | 12.7% | 15.8% | 13.8% | 15.6% | 14.3% | 10.1% | 7.8% | 4.6% |
| Net Income | 63M | 126M | 101M | 125M | 117M | 64M | 42M | 17M |
| Net Margin | 6.0% | 10.6% | 9.5% | 11.0% | 9.8% | 6.9% | 4.9% | 1.9% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | 53.0% | 70.2% | 83.5% | 95.3% | 79.6% | 34.7% | 14.1% | 3.9% |
| ROE | 17.2% | 32.3% | 28.6% | 28.2% | 26.8% | 12.8% | 8.2% | 3.2% |
| ROA | 12.0% | 22.8% | 19.4% | 19.5% | 19.5% | 10.1% | 6.1% | 2.3% |
| Cash Flow | ||||||||
| Op. Cash Flow | 124M | 152M | 127M | 160M | 121M | 71M | 61M | 32M |
| Free Cash Flow | 111M | 141M | 110M | 145M | 108M | 56M | 51M | 19M |
| Owner Earnings | 92M | 120M | 96M | 132M | 94M | 43M | 32M | 2.4M |
| CapEx | 13M | 11M | 17M | 15M | 13M | 14M | 10M | 13M |
| Maint. CapEx | 16M | 17M | 15M | 14M | 13M | 13M | 15M | 15M |
| Growth CapEx | 0 | 0 | 1.8M | 1.3M | 0 | 1.8M | 0 | 0 |
| D&A | 16M | 17M | 15M | 14M | 13M | 13M | 15M | 15M |
| CapEx/OCF | 10.7% | 7.5% | 13.1% | 9.4% | 10.5% | 20.5% | 16.5% | 40.7% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 50M | 105M | 150M | 57M | 178M | 12M | 9.4M | 9.4M |
| Buyback Yield | 3.3% | 5.6% | 5.7% | 3.1% | 9.2% | 1.1% | 1.0% | 2.8% |
| Stock-Based Comp | 15M | 15M | 16M | 14M | 14M | 15M | 15M | 15M |
| Debt Repayment | 0 | 0 | 65K | 46K | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -145M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 145M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.43 | 0.42 | 0.47 | 0.45 | 0.37 | 0.27 | 0.30 | 0.00 |
| Interest Coverage | 2880.5 | 5232.0 | 2215.0 | 348.1 | 2985.8 | 355.2 | 236.0 | 236.0 |
| Equity | 363M | 391M | 352M | 442M | 434M | 497M | 532M | 528M |
| Total Assets | 519M | 554M | 517M | 641M | 597M | 633M | 748M | 727M |
| Total Liabilities | 156M | 163M | 165M | 199M | 162M | 136M | 162M | 145M |
| Intangibles | 53M | 49M | 46M | 48M | 50M | 47M | 296M | 296M |
| Retained Earnings | 288M | 330M | 306M | 383M | 392M | 445M | 479M | 479M |
| Working Capital | 199M | 244M | 193M | 257M | 241M | 299M | 140M | 140M |
| Current Assets | 340M | 392M | 329M | 425M | 384M | 418M | 279M | 279M |
| Current Liabilities | 141M | 149M | 136M | 168M | 144M | 119M | 140M | 140M |
| Per Share Data | ||||||||
| EPS | 2.53 | 5.12 | 4.41 | 5.86 | 5.73 | 3.30 | 2.19 | 0.90 |
| Owner EPS | 3.73 | 4.88 | 4.23 | 6.22 | 4.62 | 2.24 | 1.66 | 0.13 |
| Book Value | 14.69 | 15.87 | 15.43 | 20.76 | 21.37 | 25.72 | 27.73 | 28.89 |
| Cash Flow/Share | 5.01 | 6.17 | 5.56 | 7.54 | 5.96 | 3.65 | 3.18 | 1.72 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 24.7M | 24.7M | 22.8M | 21.3M | 20.3M | 19.3M | 19.2M | 18.3M |
| Valuation | ||||||||
| P/E Ratio | 24.5 | 14.9 | 26.0 | 14.7 | 16.7 | 17.0 | 22.2 | 20.2 |
| P/FCF | 13.8 | 13.4 | 23.7 | 12.6 | 17.9 | 19.3 | 18.3 | 17.8 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.5 |
| Price/Book | 4.2 | 4.8 | 7.4 | 4.1 | 4.5 | 2.2 | 1.8 | 0.6 |
| Price/Sales | 1.5 | 1.3 | 2.4 | 1.4 | 1.7 | 1.4 | 1.3 | 0.4 |
| FCF Yield | 7.2% | 7.5% | 4.2% | 7.9% | 5.6% | 5.2% | 5.5% | 5.6% |
| Market Cap | 1.5B | 1.9B | 2.6B | 1.8B | 1.9B | 1.1B | 932M | 332M |
| Avg. Price | 62.65 | 62.77 | 109.79 | 76.81 | 98.04 | 67.99 | 58.63 | 18.17 |
| Year-End Price | 61.90 | 76.25 | 114.64 | 85.99 | 95.55 | 56.11 | 48.55 | 18.17 |
USANA HEALTH SCIENCES INC passes 5 of 9 quality checks, suggesting mixed fundamentals.
USANA HEALTH SCIENCES INC trades at 20.2x trailing earnings, compared to its 15-year median P/E of 17.0x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 17.8x vs a median of 17.9x. The company's 5-year average ROIC is 61.5% with a gross margin of 81.5%. Total shareholder yield (buybacks) is 2.8%. At current prices, the estimated annualized return to fair value is -14.1%.
USANA HEALTH SCIENCES INC (USNA) has a current P/E ratio of 20.2, compared to its historical median P/E of 17.0. The stock is currently considered Fair based on its historical valuation range.
USANA HEALTH SCIENCES INC (USNA) has a 5-year average return on invested capital (ROIC) of 61.5%. This indicates strong capital allocation and a potential competitive advantage.
USANA HEALTH SCIENCES INC (USNA) has a market capitalization of $332M. It is classified as a small-cap stock.
USANA HEALTH SCIENCES INC (USNA) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 2.84%.
Based on historical P/E analysis, USANA HEALTH SCIENCES INC (USNA) appears fair. The current P/E of 20.2 is 19% above its historical median of 17.0. The estimated fair value CAGR (P/E method) is -15.1%.
USANA HEALTH SCIENCES INC (USNA) operates in the Medicinal Chemicals & Botanical Products industry, within the Healthcare sector.
USANA HEALTH SCIENCES INC (USNA) reported annual revenue of $855 million in its most recent fiscal year, based on SEC EDGAR filings.
USANA HEALTH SCIENCES INC (USNA) has a net profit margin of 4.9%. This is a modest margin.
USANA HEALTH SCIENCES INC (USNA) generated $51 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
USANA HEALTH SCIENCES INC (USNA) has a debt-to-equity ratio of 0.30. This indicates a conservatively financed balance sheet.
USANA HEALTH SCIENCES INC (USNA) reported earnings per share (EPS) of $2.19 in its most recent fiscal year.
USANA HEALTH SCIENCES INC (USNA) has a return on equity (ROE) of 8.2%. This indicates moderate shareholder returns.
USANA HEALTH SCIENCES INC (USNA) has a 5-year average gross margin of 81.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for USANA HEALTH SCIENCES INC (USNA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
USANA HEALTH SCIENCES INC (USNA) has a book value per share of $27.73, based on its most recent annual SEC filing.